RecruitingPhase 3NCT07580300

Proton Versus Photon Therapy in Head and Neck Squamous Cell Carcinomas.

PRORADNOR-RCT Proton Versus Photon Therapy in Head and Neck Squamous Cell Carcinomas. A Randomised, Multicentre, Phase III Clinical Trial.


Sponsor

Oslo University Hospital

Enrollment

400 participants

Start Date

Apr 28, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

A national, randomized, clinical trial (phase III) investigating radiotherapy with protons compared with photons for patients with squamous cell carcinoma of the head and neck area eligible for radiotherapy, either radical or postoperative, with curative intent. Comparative dose plans with protons and photons will be prepared, and the probability of toxicity evaluated with NTCP models. Patients with presumed benefit from protons will be randomized 1:1 to treatment with protons or photons. The number of randomized participants will be 400. The primary endpoint is "combined toxicity burden" - dry mouth, difficulty swallowing, pain and affected speech in the period after the end of radiotherapy to 12 months after treatment.


Eligibility

Min Age: 40 YearsMax Age: 90 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Proton Radiotherapy for people with hnscc. The study is currently recruiting participants at 4 locations. People eligible for this study include aged 40 Years to 90 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

RADIATIONProton Radiotherapy

Proton versus Photon


Locations(4)

Haukeland University Hospital

Bergen, Norway

Oslo University Hospital, Radiumhospitalet

Oslo, Norway

University Hospital of Northern Norway

Tromsø, Norway

St. Olavs Hospital

Trondheim, Norway

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07580300


Related Trials